PUBLIC COMPANY
save$PYXSPyxis Oncology, Inc.
$PYXSBoston, MA, USupdated 13d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Mar 24, 26grantDupont Jakob · director45,867 sh
- Mar 24, 26grantWadhane Jitendra · Prin Fin & Acct Officer109,461 sh
- Mar 24, 26grantWadhane Jitendra · Prin Fin & Acct Officer262,635 sh
- Mar 24, 26grantFLAVIN JOHN L · director45,867 sh
- Mar 24, 26grantMetzger Michael A · director45,867 sh
- Mar 24, 26grantLewis-Hall Freda C · director45,867 sh
🐶 Hiring Signal
News
- Sarepta's FDA decision date; Flare gets Anna Protopapas as CEOPlus news about Deerfield, InflaRx, Praxis, Nuvectis, Pyxis Oncology, Vistagen, Arcutis Biotherapeutics and Nxera. 🔎 FDA to decide on future of Sarepta exon-skipping drugs by end of February: The…endpoints · 1mo ago
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that